November 25, the U.S. Federal Communications Commission said it had voted unanimously to adopt new norms that would prohibit the import or sale of certain technology products that pose a security risk to U.S. critical infrastructure. It was the latest in years of escalating U.S. restrictions on Chinese technology, which began under Trump and were renewed by the Biden administration.
Rosenworcel, a Democrat who chairs the commission, said in a statement, "The FCC is committed to protecting U.S. national security by ensuring that untrustworthy communications equipment is not authorized for use within our borders, and we will continue to do this work."
Under the new specifications, the U.S. will ban the sale of communications equipment made by Huawei and ZTE and restrict the use of some Chinese-made video surveillance systems, including products from Hikvision, Dahua, and Hainengda, on the grounds that they pose an unacceptable risk to U.S. national security.
The FCC's order applies to future equipment authorizations, though the agency left open the possibility that it could revoke previous authorizations.
Communications commissioner Carr, a member of the **** and GOP, tweeted, "As a result of our order, no new Huawei or ZTE equipment can be authorized. Nor can any new Dahua, Hikvision, or Hynectar equipment be approved unless they assure the FCC that their equipment will not be used for public **** security, government facility security, and other national security purposes."
The U.S. is suppressing China in the technology sector, but it's hurting for medical devices.
China is one of Europe's major trading partners in medical devices and equipment, accounting for 12 percent of exports to the European medical equipment market in 2021 alone. But the European Union and the United States argue that China is pursuing protectionist policies in the medical device sector, claiming that China takes various measures to support its domestic medical device industry.
As China is not a party to the World Trade Organization's Agreement on Government Procurement (GPA), it has only been able to negotiate verbally with China.
Pharmaceuticals and medical devices will reportedly be on the agenda of the 3rd meeting of the Committee on Trade and Technology between the U.S. government and the European Union's executive committee, which will be held in Washington on Dec. 5 next year.
The Trade and Technology Committee, established in June 2021, is an initiative organization that provides a permanent platform for transatlantic cooperation on key global trade, economic and technology issues. In the draft, the U.S. and the European Union expressed "concern about the threat posed by a range of non-market policies and practices," such as in the area of medical devices. Medical device importers report that China's tenders, which were previously open to imports, now specifically require the use of domestic products.
In response, the EU's executive committee said it had been expressing concerns about market release barriers to the Chinese authorities.
The draft from the Committee on Trade and Technology says the U.S. and EU have analyzed and exchanged relevant data and examined the market share of U.S. and EU medical device companies in China to understand the challenges of the impact on U.S. and EU companies.
In fact, it's useless for the US and EU to express any more concern, as the Chinese government has its own reasons for supporting its domestic medical device industry, which is mostly for the sake of the public. Take the cardiac stent for example, the original a cardiac stent 20,000 yuan, now the state through centralized purchasing, increase production and other measures, a cardiac stent of the same quality down to a few hundred dollars a, the quality of domestic stents is not inferior to the imported stents, so why do people have to use ultra-expensive imported cardiac stents it?